Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: A systematic review and meta-analysis

Cardiovascular Therapeutics

Volumn 32, Issue 4, 2014, Pages 184-188

  Pan, Gaofeng ^a   Zhou, Xuefeng ^a   Zhao, Jinping ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Hypertention; Meta analysis; Telmisartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ARTICLE; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; META ANALYSIS; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SINUS RHYTHM; SYSTEMATIC REVIEW; ATRIAL FIBRILLATION; CHI SQUARE DISTRIBUTION; COMPLICATION; KAPLAN MEIER METHOD; PATHOPHYSIOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BENZOATES; CHI-SQUARE DISTRIBUTION; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; ODDS RATIO; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84903944353     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12073     Document Type: Article

References (43)

1. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-711.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
3. Vidaillet H, Granada JF, Chyou PO, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002;113:365-370.
4. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-1046.
5. Stewart S, Hart CL, Hole DJ, Mcmurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-364.
6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
7. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE, ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810-815.
8. Vagaonescu TD, Wilson AC, Kostis JB. Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. Hypertension 2008;51:1552-1556.
9. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009;119:2146-2152.
10. Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens 2012;26:563-569.
11. Nattel S, Shiroshita-Takeshita A, Cardin S, Pelletier P. Mechanisms of atrial remodelling and clinical relevance. Curr Opin Cardiol 2005;20:21-25.
12. Okin PM, Gerdts E, Wachtell K, Oikarinen L, Nieminen MS, Dahlöf B, Devereux RB. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens 2010;28:1534-1540.
13. Casaclang-Verzosa G, Gersh BJ. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008;51:1-11.
14. Raitt MH, Volgman AS, Zoble RG, Charbonneau L, Padder FA, O'Hara GE, Kerr D, AFFIRM Investigators. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2006;151:390-396.
15. Toh N, Kanzaki H, Nakatani S, et al. Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of paroxysmal atrial fibrillation. Hypertension 2010;55:1150-1156.
16. Marchese P, Bursi F, Delle Donne G, et al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr 2011;12:214-221.
17. Gerdts E, Wachtell K, Omvik P, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007;49:311-316.
18. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006;296:1242-1248.
19. Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 2011;17:34-43.
20. Fogari R, Zoppi A, Maffioli P, Mugellini A, Preti P, Perrone T, Derosa G. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol 2012;35:359-364.
21. Galzerano D, Di Michele S, Paolisso G, et al. A multicenter randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. Journal of the Renin-Angiotensin-Aldosterone. System 2012;13:496-503.
22. Du HA, Fan JQ, Ling ZY, et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension 2013;61:786-792.
23. Yu H, Gao J, Wang H, et al. Effects of the renin-angiotensin system on the current I (to) in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 2000;86:1062-1068.
24. Delpon E, Caballero R, Gomez R, Nunez L, Tamargo J. Angiotensin II, Angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci 2005;26:155-161.
25. Li Y, Li W, Xue J, Yang S, Gu H. Effects of losartan on acute atrial electrical remodeling. Chin Med J 2004;117:643-646.
26. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of randomized trial. Circulation 2004;110:552-557.
27. Boldt A, Scholl A, Garbade J, Resetar ME, Mohr FW, Gummert JF, Dhein S. Ace-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 2006;101:261-267.
28. Gerdtz E, Oikarinen L, Palmieri V, Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for End-point reduction in hypertension (LIFE) study. Hypertension 2002;39:739-743.
29. Celik T, Iyisoy A, Kursaklioglu H, et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol 2005;28:298-302.
30. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336.
31. Healey JS, Baranchuk A, Crystal E. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839.
32. Kalus JS, Coleman CI, White CM. The impact of suppressing the reninangiotensin system on atrial fibrillation. J Clin Pharmacol 2006;46:21-28.
33. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-557.
34. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719.
35. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropyridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011;13:473-479.
36. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012;5:43-51.
37. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-1617.
38. Tu DN, Liao YH, Zou AR, Du YM, Run Q, Wang XP, Li L. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes. Acta Pharmacol Sin 2008;29:913-922.
39. Galetta F, Franzoni F, Fallahi P, et al. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2010;64:516-520.
40. Sengul C, Cevik C, Ozveren O, et al. Telmisartan decreases atrial electromechanical delay in patients with newly diagnosed essential hypertension. J Electrocardiol 2012;45:123-128.
41. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-46.
42. Yusuf S, Teo KK, Pogue J, ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
43. Verdecchia P. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease studies. J Hypertens 2012;30:1004-1014.